<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Genetic testing and diagnostic company BillionToOne has entered an agreement with Janssen R&amp;D, a company of Johnson &amp; Johnson, to perform a global clinical trial for severe hemolytic disease.
      </p>
    </li>
    <li>
      <p>
        The partnership will leverage BillionToOne's UNITY Fetal Antigen Clinical Trial Assay (CTA) to select suitable participants for its critical Phase III trial in handling severe hemolytic diseases in pregnancy. The collaborations could lead to the development of a non-invasive prenatal test that detects incompatible blood types between a pregnant individual and a fetus.&nbsp;
      </p>
    </li>
    <li>
      <p>
        The assay is expected to receive regulatory approval from health authorities globally as the trial progresses, and it will be implemented across the US, European Union, and certain other countries.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/billiontoone-announces-global-collaboration-to-provide-its-unity-fetal-antigen-clinical-trial-assay-in-johnson--johnson-phase-3-clinical-trial-of-nipocalimab-in-hemolytic-disease-of-the-fetus-and-newborn-302011805.html">
      Press release
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 <p>Genetic testing firm BillionToOne has partnered with Janssen R&amp;D, a Johnson &amp; Johnson company, to conduct a global clinical trial for severe hemolytic disease. They will use BillionToOne's UNITY Fetal Antigen Clinical Trial Assay (CTA) to select participants for a critical Phase III trial. The partnership might result in a non-invasive prenatal test that detects blood type incompatibility between a pregnant person and a fetus. The assay is expected to receive global regulatory approval as the trial advances and is aiming to be implemented across the US, European Union, and other select countries.</p>
</div>

All Updates

BillionToOne collaborates with Janssen to perform clinical trial in hemolytic disease

BillionToOne raises USD 83.5 million in private funding and loan facility; shows clinical performance of Unity test